{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:33:13Z","timestamp":1791657193852,"version":"4.3.4"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Model\u2010informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia\u2010inducible factor prolyl hydroxylase (HIF\u2010PHI) inhibitor aimed at treating anemia in chronic kidney disease patients. MIDD was pivotal in optimizing dosing strategies and enabling effective dose individualization, ensuring the right dose for the right patient. This tutorial illustrates how integrated quantitative approaches, including longitudinal hemoglobin response modeling, population pharmacokinetics (PopPK), and clinical trial simulations, were applied to guide phase III dose selection, inform trial design, and support regulatory interactions. We highlight the evolution and application of these models, emphasizing key development decisions, challenges encountered, and insights gained.<\/jats:p>","DOI":"10.1002\/cpt.70094","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:45:08Z","timestamp":1761972308000},"page":"322-335","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Model\u2010Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia"],"prefix":"10.1002","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-2149","authenticated-orcid":false,"given":"Kelly M.","family":"Mahar","sequence":"first","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9841-2342","authenticated-orcid":false,"given":"Shuying","family":"Yang","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3737-7146","authenticated-orcid":false,"given":"Brendan","family":"Johnson","sequence":"additional","affiliation":[{"name":"GSK  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2186-7195","authenticated-orcid":false,"given":"Sandra A.G.","family":"Visser","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2241-3001","authenticated-orcid":false,"given":"Paul","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&amp;P)  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7016-2846","authenticated-orcid":false,"given":"Martijn","family":"van Noort","sequence":"additional","affiliation":[{"name":"Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&amp;P)  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-2678","authenticated-orcid":false,"given":"Teun M.","family":"Post","sequence":"additional","affiliation":[{"name":"Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&amp;P)  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23262-1"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.19"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1414347"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12049"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12633"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.54"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1363"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100235"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00299.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084943"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-200205000-00011"},{"key":"e_1_2_8_12_1","unstructured":"United States Renal Data System.2023 USRDS Annual Data Report: Epidemiology of kidney disease in the United States(2023) <https:\/\/adr.usrds.org\/2023>."},{"key":"e_1_2_8_13_1","unstructured":"Epogen (epoetin alfa) FDA Label.Highlights of prescribing information. Accessed 30 July 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103234s5363s5366lbl.pdf."},{"key":"e_1_2_8_14_1","unstructured":"Aranesp (Darbepoetin alfa) FDA Label. Highlights of prescribing information. Accessed 30 July 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103951orig1s5173_103951orig1s5258lbl.pdf."},{"key":"e_1_2_8_15_1","volume-title":"JESDUVROQ (Daprodustat). [Package insert]","author":"GlaxoSmithKline","year":"2024"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13835"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.011"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.16011219"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1029"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080364"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010377201"},{"key":"e_1_2_8_22_1","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"MacMurray J.","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000513103"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12962"},{"key":"e_1_2_8_25_1","article-title":"Population kinetic\/pharmacodynamic (K\/PD) analyses of daprodustat (prolyl hydroxylase inhibitor) in non\u2010dialysis (ND) and hemodialysis\u2010dependent (HDD) anemia patients with chronic kidney disease (CKD)","volume":"45","author":"Mahar K.M.","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.03.031"},{"key":"e_1_2_8_27_1","unstructured":"US Food and Drug Administration.Model\u2010informed drug development pilot program<https:\/\/www.fda.gov\/drugs\/development\u2010resources\/model\u2010informed\u2010drug\u2010development\u2010pilot\u2010program>. Accessed October 11 2024."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3245"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2919"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12866"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3228"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1933"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2162"},{"issue":"64","key":"e_1_2_8_34_1","first-page":"T040","article-title":"Population pharmacokinetic (POP\u2010PK) analysis of Daprodustat (GSK1278863) and its metabolites in non\u2010dialysis (ND) and hemodialysis\u2010dependent (HDD) anemia patients with chronic kidney disease (CKD)","volume":"45","author":"Mahar K.","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1","key":"e_1_2_8_35_1","article-title":"Population pharmacokinetic analysis of daprodustat in healthy volunteers (HV), global phase 2 and Japanese phase 3 studies in chronic kidney disease patients with anemia following once daily (QD) or 3 times weekly (TIW) administration","volume":"109","author":"Post T.","year":"2021","journal-title":"Clin. Pharm. Ther."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01417-9"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.83"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3215"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3544"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.02.019"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00550122"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy013"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab065"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab318"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03257-3"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70094","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:15:26Z","timestamp":1770894926000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cpt.70094"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70094","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}